Patients aged 40–65 years who had type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%–10% type 2 Diabetes who had inadequate glycaemic control
Conditions
Interventions
receive diacerein 50 mg once-
daily for 12 weeks,receive placebo tablets once-
daily for 12 weeks
Active Comparator Drug,Placebo Comparator No treatment
Treated Group,Placebo Group
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: Type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%–10%
Exclusion criteria
Exclusion criteria: Patients who had chronic inflammatory disease, chronic steroid use, serum creatinine level >2 mg/dL or eGFR <60 ml/min/1.73 m2/day, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels more than three times the upper normal limit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an accurate-mass quadrupole time-of-flight mass spectro,Metabolic biomarkers for coronary artery disease in inadequately controlled type 2 Diabetes 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate-mass quadrupole time-of-fl,The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate-mass quadrupole time-of-fl,The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncont 2 year performance liquid chromatography coupled to an Agilent 6540 UHD accurate-mass quadrupole time-of-fl | — |
Secondary
| Measure | Time frame |
|---|---|
| none none none | — |
Countries
Thailand
Contacts
Public ContactJintanan Jangsiripornpakorn
Ramathibodi Hospital
Outcome results
None listed